This study has established a bridge between the microscopic RNA modification mechanism of m6A and the macroscopic clinical manifestations of PAAD patients, highlighting the value of m6A regulatory genes, especially IGF2BP2, in the pathogenesis, diagnosis and treatment of PAAD. Here, IGF2BP2 is linked to pancreatic adenocarcinoma.